LivaNova (LIVN Stock): Double-Digit Growth by Making Healthcare AffordableLivaNova (LIVN) sits at the intersection of strong financial execution and life-changing medical innovation, benefiting from rising global demand for cardiopulmonary and neuromodulation therapies. With 10% organic revenue growth in Q2 2025, expanding margins, and a robust balance sheet, the company combines consistent growth momentum with market leadership in heart-lung machines and VNS therapy. Beyond the numbers, LivaNova delivers measurable healthcare impact by addressing critical unmet needs in cardiac surgery, drug-resistant epilepsy, depression, and sleep apnea—making LIVN stock a compelling blend of performance and purpose.
February 10, 2026